lisocabtagene maraleucel demonstrates improvement over standard of care in 2l lbcl
Published 2 years ago • 85 plays • Length 11:04Download video MP4
Download video MP3
Similar videos
-
6:40
frederick locke: axi-cel vs. standard of care in aggressive lbcl
-
6:04
tisagenlecleucel shows no efs improvement on standard of care in 2l for aggressive b-cell nhl
-
5:04
transform: phase iii study of liso-cel versus standard of care for r/r lbcl
-
4:59
zuma-7: axi-cel is superior to standard of care across common prognostic subgroups in r/r lbcl
-
6:19
lisocabtagene maraleucel is efficacious at treating r/r cll/sll
-
2:46
transform: liso-cel versus standard of care as second-line therapy for r/r lbcl
-
5:26
treatment options for diffuse large b-cell lymphoma (dlbcl)
-
4:54
understanding diffuse large b-cell lymphoma (dlbcl)
-
6:46
dr. luminari remarks on eu approval of odronextamab for dlbcl, follicular lymphoma
-
4:26
axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large b-cell lymphoma
-
1:19
real-world outcomes of liso-cel therapy in r/r dlbcl
-
2:27
lisocabtagene maraleucel for r/r mcl: transcend-nhl-001 update
-
2:08
dr. ghosh on the benefits of lisocabtagene maraleucel in relapsed/refractory nhl
-
1:37
liso-cel for r/r large b-cell lymphoma
-
3:59
3-year follow-up from the transform trial: liso-cel is superior to soc in r/r dlbcl
-
0:58
improving second-line treatments in dlbcl
-
2:52
mosunetuzumab for chemotherapy-intolerant dlbcl
-
2:39
axi-cel improves survival in early r/r large b-cell lymphoma
-
4:53
interim analysis of transform: liso-cel vs soc in high-risk r/r lbcl
-
7:35
axicabtagene ciloleucel provides superior efs vs standard of care in elderly with relapsed/refra...
-
9:04
dr. michael chu on outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety...
-
3:29
car-t therapy as the soc in 2l lbcl and barriers that remain